Compare DexCom, Inc. (DXCM) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Northrop Grumman Corporation — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Northrop Grumman Corporation trades at $524.58 (market cap $74.60B). The key difference: Northrop Grumman Corporation is far larger — about 2.7× DexCom, Inc.'s market cap, and Northrop Grumman Corporation pays a 1.79% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NOC | |
|---|---|---|
Market Cap | $28.06B | $74.60B |
Sector | Health | Industrials |
52-Week High | $89.53 | $768.02 |
52-Week Low | $54.84 | $496.02 |
Enterprise Value | $27.03B | $88.82B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Northrop Grumman (NOC) trades at $528.67, down 2.43% amid broader defense sector weakness. The stock shows strong fundamentals with consistent earnings beats, a 10.8% net margin, and $95.6B backlog supporting revenue visibility. Technical indicators signal bearish momentum with price near support at $523, while RSI at 24 suggests potential oversold conditions. Recent news highlights expansion in missile defense and space systems amid increased NATO spending expectations.
NOC presents a compelling value opportunity with 57% analyst buy ratings and $655 price target implying 24% upside. Key catalysts include Q2 earnings beat potential and defense budget tailwinds, though political uncertainty and execution risks on large contracts remain concerns. The stock's 16.5 P/E ratio appears attractive relative to historical averages given its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
